How can we tailor treatment to improve outcome in MDS?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Rena Buckstein, Sunnybrook Health Sciences Centre, Toronto, CA. We asked, How can we tailor treatment to improve outcome in MDS?

In this video, Buckstein outlines outcomes that could be improved by tailored treatment, such as overall survival, leukemia-free survival, and quality of life. She talks about the importance of next-generation sequencing in identifying mutations and clarifying diagnosis and prognosis, as well as permitting personalization of therapy. Buckstein goes on to discuss ongoing studies and promising treatments available for patients with MDS.